Sporadic Blau syndrome treated with adalimumab

Clin Exp Dermatol. 2019 Oct;44(7):811-813. doi: 10.1111/ced.14016. Epub 2019 Jun 24.

Authors

G W M Millington¹, J Dobson¹, S Holden², G Waters³, N Puvanachandra⁴, R Close⁵, P Bale⁵, K Armon⁵

Affiliations

¹ Department of, Dermatology, Norfolk and Norwich University Hospital, Norwich, UK.
² Department of, Clinical Genetics, Cambridge University Hospitals, Cambridge, UK.
³ Department of, Cellular Pathology, Norfolk and Norwich University Hospital, Norwich, UK.
⁴ Department of, Ophthalmology, Norfolk and Norwich University Hospital, Norwich, UK.
⁵ Department of, Paediatric Rheumatology, Cambridge University Hospitals, Cambridge, UK.

PMID: 31232485
DOI: 10.1111/ced.14016

No abstract available

Publication types

Case Reports

MeSH terms

Acute Disease
Adalimumab / administration & dosage
Adalimumab / therapeutic use
Anti-Inflammatory Agents / administration & dosage
Anti-Inflammatory Agents / therapeutic use
Arthritis / diagnosis
Arthritis / drug therapy
Arthritis / genetics*
Arthritis / pathology*
Diagnosis, Differential
Exanthema / diagnosis
Exanthema / etiology*
Female
Humans
Infant
Nod2 Signaling Adaptor Protein / genetics
Sarcoidosis
Synovitis / drug therapy
Synovitis / genetics*
Synovitis / pathology*
Treatment Outcome
Uveitis / diagnosis
Uveitis / drug therapy
Uveitis / genetics*
Uveitis / pathology*

Substances

Anti-Inflammatory Agents
NOD2 protein, human
Nod2 Signaling Adaptor Protein
Adalimumab

Supplementary concepts

Blau syndrome